Dexamethasone Added to Intensive Chemotherapy in Older Patients With Acute Myeloid Leukemia (AML)
Status:
Active, not recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Recent preclinical and clinical data strongly suggested that dexamethasone could improve the
activity of intensive chemotherapy in AML. In this study, the FILO study group will assess
the impact of adding dexamethasone to both induction and consolidation therapy in older AML
patients with intermediate or favorable risk.